US2974787A - Single use, prepackaged vaccinator - Google Patents

Single use, prepackaged vaccinator Download PDF

Info

Publication number
US2974787A
US2974787A US28109A US2810960A US2974787A US 2974787 A US2974787 A US 2974787A US 28109 A US28109 A US 28109A US 2810960 A US2810960 A US 2810960A US 2974787 A US2974787 A US 2974787A
Authority
US
United States
Prior art keywords
bubble
plastic
prepackaged
vaccinator
prongs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US28109A
Inventor
Cooper Murray Sam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US28109A priority Critical patent/US2974787A/en
Application granted granted Critical
Publication of US2974787A publication Critical patent/US2974787A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205Vaccinating by means of needles or other puncturing devices

Definitions

  • Intracutaneous injections are used to vaccinate against diseases such as smallpox and diagnostically to test for tuberculosis and for the diagnosis of histoplasmosis, blastomycosis, coccidimycosis, cryptococcosis, sporotrichosis, and for allergic reactions towards tetanus, penicillin, horse serum or any of the other group of materials, including proteins, towards which allergic sensitivities may occur.
  • the present prepackaged vaccinator is an improvement in which the plastic bubble containing the biologicalliquid is united, preferably adhesively, to a backing strip and is surrounded by an absorbent material, such as blotting paper.
  • the plastic bubble is protected by apertured spar ers and is enclosed in a sterile enclosure conveniently of plastic sheets, the entire bubble assembly being externally sterile so that the sterile enclosure may be opened and the biological liquid administered by pressing the bubble against the skin of the subject to cause the prongs of the injector plate to penetrate both the plastic bubble and the skin.
  • the skin must be cleansed in accordance with the usual procedures, but the external surface of the plastic bubble and its contents are ready for use without additional treatment or operations.
  • the immediate and ready availability of the prepackaged vaccinator enable an unskilled assistant to vaccinate or test large numbers of subjects rapidly, economically, eificiently, 'and with a risk of secondary infection.
  • the blotting material which surrounds the plastic bubble may be of blotting paper or absorbent gauze, or other liquid-absorbing material. By absorbing any biological liquid which escapes from the plastic bubble such biological liquid is prevented from coming in contact with the hands of the administrator. This protects the hands of the administrator, which could become sensitive towards particular biological liquids, and also reduces the possibility of the administrator inadvertently transferring a biological liquid which could otherwise escape onto the administrators hands and be transferred to a second patient, or a difierent area on the first patient.
  • Figure 1 is a pictorial view of an assembled prepackaged vaocinator.
  • Figure 2 is a cross section of an assembled prepackaged vaccinator.
  • Figure 3 is a pictorial, in partial section, of a modification using an internally pronged injector in the bubble.
  • Figure 4 is a pictorial, in partial section, of a multiple pronged injector in a bubble.
  • the prepackaged vaccinator comprises an injector plate 11 which conveniently is a square plate having a cut-out hole 13, to reduce its weight and permit freer circulation of the liquid bubble contents, and which square plate has thereon a plurality of pron-gs 14.
  • these prongs are externally formed on the square plate with two prongs adjacent each of four corners, which prongs are bent at an angle of with the square plate, thus bringing the two prongs at a corner into juxtaposition with a gap 16 between each pair of prongs. It is preferred that all of the points 15 of the prongs be in approximately the same plane with the prongs having the same length.
  • the injector plate is enclosed in a plastic bubble 17 comprising a rounded bubble cover 18 peripherally sealed to a bubble fiat 19.
  • the bubble cover and the bubble fiat may be adhesively sealed, but are more conveniently heat sealed to form a hermetically sealed enclosure.
  • the bubble is fastened to a backing strip 20 which conveniently is a square of cloth to which the bubble is united with an adhesive 21. Ordinary adhesive tape with a moisture-proof backing gives good results.
  • a backing strip 20 which conveniently is a square of cloth to which the bubble is united with an adhesive 21.
  • Ordinary adhesive tape with a moisture-proof backing gives good results.
  • an absorbent material 22 Surrounding the plastic bubble and also adherent to the backing strip is an absorbent material 22 which conveniently is blotting paper. Other absorbent materials, such as gauze and cotton, may be used.
  • the absorbent material should have sufficient absorptive capacity to ensure that the liquid contents of the bubble are absorbed rather than flowing from under the backing strip on administration.
  • the plastic bubble is protected by apertured spacers 23 which are in contact with the absorbent material and surround the plastic bubble with the aperture of suflicient size to contain the plastic bubble.
  • apertured spacers 23 which are in contact with the absorbent material and surround the plastic bubble with the aperture of suflicient size to contain the plastic bubble.
  • One thicker or a group of thinner spacers may be used.
  • the spacers are of cardboard stacked to sufficient thickness to protect the bubble containing the injector plate from pressure.
  • the backing strip with the bubble and the apertured spacers is enclosed in a sterile enclosure 27 which consists of an upper plastic sheet 24 and a lower plastic sheet 25, which are connected to each other by an edge seal 26.
  • the biological liquid 28 above referred to may be any of a wide variety of biological agents, the selection of which is within the skill of the art.
  • the plastic sheets 24 and 25 be such that the final assembly may be sterilized by passing carbon such as the Freons, to reduce the explosive hazard, throughthe plastic sheets to sterilize the inside of the sterile enclosure. If the biological liquid sensitive to such agent, the bubble should be impermeableto the gaseous sterilizing agent during the sterilizing cycle.
  • An internal bubble of a polymer of ethylene glycol and terephthalic acid (Mylar) is satisfactory.
  • Other plastics may be used, including polyethylene films, rubber hydrochloride, nylon, etc.
  • a thickness of at least 0.0005 may be used; a. thickness of more than 0.005 can become difficult to penetrate during use.
  • the outer envelope forming the sterile enclosure can be of cellophane, polyethylene, etc.
  • the plastic films may be modified accordingly.
  • sterilize the plastic from which the plastic bubble is formed using a sterile bubble cover and a sterile bubble flat which are filled with the biological liquid and the sterile injector plate aseptically.
  • a clean but not sterile assembly system may be used where the biological liquid is sufficiently resistant to stand a gaseous heat or radiation sterilizing cycle, with sterilization after assembly. Such method of assembly is largely determined by the characteristics of the specific biological liquid being administered.
  • the inside of the bubble should be sterile, except for any desired biological activity.
  • the exact size and shape of the bubble and the quantity of biological liquid and its characteristics are selected to meet the particular situation. Usually, a couple of drops of biological liquid with an injector plate A of an inch on a side gives rapid and reliable results. Larger or smaller embodiments may be used depending on the strength of a particular biological liquid, the dosage required, and the thickness of the skin ofthe proposed subject.
  • the prepackaged vaccinator is frequentlyused on human subjects, but can be used on animals.
  • a prong length of 1 to 10 millimeters is usually suflicient for such uses.
  • a prong length of 2 to 5 millimeters is especially useful on humans.
  • the outer sterile enclosure is broached and the plastic bubble sterilely removed, the spacer discarded, the bubble cover placed against a clean skin surface, and pressure applied through the backing strip which causes the points of the prongs to penetrate the bubble cover and the skin of the subject, carrying with them the dosage of biological liquid.
  • FIG. 3 A separate modification of the plastic bubble is shown in Figure 3 in which four prongs are formed by being cut out internally of the injector plate so that the four prongs are adjacent to a rectangular cut out hole.
  • FIG. 4 A third embodiment is shown in Figure 4, in which an injector plate is used, having a plurality 0t prongs punched from the plate.
  • an 'injecto'r plate having pointed, penetrating prongs, a penetrable plastic bubble enclosing said plate, a biologi cal liquid in said bubble with said injector plate, a backing strip to which the bubble is attached, an absorbent material surrounding the plastic bubble, and also attached to the backing strip, at least one apertured spacer surrounding the plastic bubble, and a sterile enclosure inwhich the bubble, backing strip, absorbent material and spacer are sterilely protected from external contamination and from which the bubble and its contents may be sterilely removed.
  • a single use, prepackaged vaccinator comprising: an injector plate having pointed, penetrating prongs, a penetrable plastic bubble enclosing said plate, a biological liquid in said'bubble with said injector plate, a backing strip to which the bubble is adhesively united, an absorbent material surrounding the plastic bubble and adhesively united to the backing strip, at least one aper tured spaced surrounding the plastic bubble, and a sterile enclosure which the bubble, backing strip, absorbent material and spacer are sterilely protected from external contamination-and from which the bubble and its contents may he sterilely removed.

Description

March 14, 1961 M. S. COOPER SINGLE USE, PREPACKAGED VACCINATOR Filed May 10, 1960 IN VEN TOR. MHZ/P11) 5AM 600/25? BY M 4441mm United States Patent SINGLE USE, PREPACKAGED VACCINATOR Murray Sam Cooper, Dumont, NJ., assignor to American Cyanamid Company, New York, N.Y., a corporation of Maine Filed May 10, 1960, Ser. No. 28,109
2 Claims. (Cl. 206-632) punctures the plastic bubble and carries on its prongs the biologically-active fluid; the plastic bubble being attached to a backing strip and being surrounded by an absorbent material.
Intracutaneous injections are used to vaccinate against diseases such as smallpox and diagnostically to test for tuberculosis and for the diagnosis of histoplasmosis, blastomycosis, coccidimycosis, cryptococcosis, sporotrichosis, and for allergic reactions towards tetanus, penicillin, horse serum or any of the other group of materials, including proteins, towards which allergic sensitivities may occur.
Sealed envelopes containing a biologic fluid and an injection device adapted to penetrate the envelope and the epidermis of a test subject have been disclosed previously, including the disclosure in United States Patent. No. 2,893,392, A. R. Wagner and M. S. Cooper, Article of Manufacture for Intracutaneous Injections, July 7, 1959. The present prepackaged vaccinator is an improvement in which the plastic bubble containing the biologicalliquid is united, preferably adhesively, to a backing strip and is surrounded by an absorbent material, such as blotting paper. The plastic bubble is protected by apertured spar ers and is enclosed in a sterile enclosure conveniently of plastic sheets, the entire bubble assembly being externally sterile so that the sterile enclosure may be opened and the biological liquid administered by pressing the bubble against the skin of the subject to cause the prongs of the injector plate to penetrate both the plastic bubble and the skin. The skin must be cleansed in accordance with the usual procedures, but the external surface of the plastic bubble and its contents are ready for use without additional treatment or operations.
The immediate and ready availability of the prepackaged vaccinator enable an unskilled assistant to vaccinate or test large numbers of subjects rapidly, economically, eificiently, 'and with a risk of secondary infection.
The blotting material which surrounds the plastic bubble may be of blotting paper or absorbent gauze, or other liquid-absorbing material. By absorbing any biological liquid which escapes from the plastic bubble such biological liquid is prevented from coming in contact with the hands of the administrator. This protects the hands of the administrator, which could become sensitive towards particular biological liquids, and also reduces the possibility of the administrator inadvertently transferring a biological liquid which could otherwise escape onto the administrators hands and be transferred to a second patient, or a difierent area on the first patient.
In testing for allergies, it is quite common to simultaneously administer a number of possible allergens to different areas of the skin of a subject and, by reading 7 Patented Mar. 14, 1961 the elfect of each on the skin, determine which of the allergens elicits a response on a specific subject. Inasmuch as the reading is based on a local area of reaction, it is essential that the test liquid for each area be confined to that area. If a biological liquid is allowed to escape and come in contact with the fingers of an administrator, biologically-active material can be inadvertently transferred; thus compromising the reliability of the results.
Other uses and advantages of the present prepackaged vaccinator are apparent to those skilled in the art from the descriptions of certain embodiments of the present invention which are shown in the accompanying drawings.
Figure 1 is a pictorial view of an assembled prepackaged vaocinator.
Figure 2 is a cross section of an assembled prepackaged vaccinator.
Figure 3 is a pictorial, in partial section, of a modification using an internally pronged injector in the bubble.
Figure 4 is a pictorial, in partial section, of a multiple pronged injector in a bubble.
Referring more particularly to the cross section of the embodiment shown in Figure 2, the prepackaged vaccinator comprises an injector plate 11 which conveniently is a square plate having a cut-out hole 13, to reduce its weight and permit freer circulation of the liquid bubble contents, and which square plate has thereon a plurality of pron-gs 14. As shown in Figure 2, these prongs are externally formed on the square plate with two prongs adjacent each of four corners, which prongs are bent at an angle of with the square plate, thus bringing the two prongs at a corner into juxtaposition with a gap 16 between each pair of prongs. It is preferred that all of the points 15 of the prongs be in approximately the same plane with the prongs having the same length. The gap between the prongs, by capillarity, attracts and holds the biological liquid to be administered. The injector plate is enclosed in a plastic bubble 17 comprising a rounded bubble cover 18 peripherally sealed to a bubble fiat 19. The bubble cover and the bubble fiat may be adhesively sealed, but are more conveniently heat sealed to form a hermetically sealed enclosure.
The bubble is fastened to a backing strip 20 which conveniently is a square of cloth to which the bubble is united with an adhesive 21. Ordinary adhesive tape with a moisture-proof backing gives good results. Surrounding the plastic bubble and also adherent to the backing strip is an absorbent material 22 which conveniently is blotting paper. Other absorbent materials, such as gauze and cotton, may be used. The absorbent material should have sufficient absorptive capacity to ensure that the liquid contents of the bubble are absorbed rather than flowing from under the backing strip on administration.
In the final assembly, the plastic bubble is protected by apertured spacers 23 which are in contact with the absorbent material and surround the plastic bubble with the aperture of suflicient size to contain the plastic bubble. One thicker or a group of thinner spacers may be used. Preferably, the spacers are of cardboard stacked to sufficient thickness to protect the bubble containing the injector plate from pressure. The backing strip with the bubble and the apertured spacers is enclosed in a sterile enclosure 27 which consists of an upper plastic sheet 24 and a lower plastic sheet 25, which are connected to each other by an edge seal 26.
Inside the plastic bubble is the biological liquid 28 above referred to. The biological liquid may be any of a wide variety of biological agents, the selection of which is within the skill of the art.
It is preferred that the plastic sheets 24 and 25 be such that the final assembly may be sterilized by passing carbon such as the Freons, to reduce the explosive hazard, throughthe plastic sheets to sterilize the inside of the sterile enclosure. If the biological liquid sensitive to such agent, the bubble should be impermeableto the gaseous sterilizing agent during the sterilizing cycle. An internal bubble of a polymer of ethylene glycol and terephthalic acid (Mylar) is satisfactory. Other plastics may be used, including polyethylene films, rubber hydrochloride, nylon, etc. A thickness of at least 0.0005 may be used; a. thickness of more than 0.005 can become difficult to penetrate during use.
The outer envelope forming the sterile enclosure can be of cellophane, polyethylene, etc. i
If other sterilizing conditions are used, such as radiation or heat, the plastic films may be modified accordingly. Usually, it is most convenient to sterilize the plastic from which the plastic bubble is formed using a sterile bubble cover and a sterile bubble flat which are filled with the biological liquid and the sterile injector plate aseptically. A clean but not sterile assembly system may be used where the biological liquid is sufficiently resistant to stand a gaseous heat or radiation sterilizing cycle, with sterilization after assembly. Such method of assembly is largely determined by the characteristics of the specific biological liquid being administered. The inside of the bubble should be sterile, except for any desired biological activity. i
The exact size and shape of the bubble and the quantity of biological liquid and its characteristics are selected to meet the particular situation. Usually, a couple of drops of biological liquid with an injector plate A of an inch on a side gives rapid and reliable results. Larger or smaller embodiments may be used depending on the strength of a particular biological liquid, the dosage required, and the thickness of the skin ofthe proposed subject. The prepackaged vaccinator is frequentlyused on human subjects, but can be used on animals.
A prong length of 1 to 10 millimeters is usually suflicient for such uses. A prong length of 2 to 5 millimeters is especially useful on humans.
In use, the outer sterile enclosure is broached and the plastic bubble sterilely removed, the spacer discarded, the bubble cover placed against a clean skin surface, and pressure applied through the backing strip which causes the points of the prongs to penetrate the bubble cover and the skin of the subject, carrying with them the dosage of biological liquid.
A separate modification of the plastic bubble is shown in Figure 3 in which four prongs are formed by being cut out internally of the injector plate so that the four prongs are adjacent to a rectangular cut out hole.
A third embodiment is shown in Figure 4, in which an injector plate is used, having a plurality 0t prongs punched from the plate.
These and other modifications are apparent to those skilled in the art, and come within the scope of the present invention which is set forth in the appended claims.
1 claim:
lJA-singIe use, prepackaged vaccinator comprising:
an 'injecto'r plate having pointed, penetrating prongs, a penetrable plastic bubble enclosing said plate, a biologi cal liquid in said bubble with said injector plate, a backing strip to which the bubble is attached, an absorbent material surrounding the plastic bubble, and also attached to the backing strip, at least one apertured spacer surrounding the plastic bubble, and a sterile enclosure inwhich the bubble, backing strip, absorbent material and spacer are sterilely protected from external contamination and from which the bubble and its contents may be sterilely removed. 2. A single use, prepackaged vaccinator comprising: an injector plate having pointed, penetrating prongs, a penetrable plastic bubble enclosing said plate, a biological liquid in said'bubble with said injector plate, a backing strip to which the bubble is adhesively united, an absorbent material surrounding the plastic bubble and adhesively united to the backing strip, at least one aper tured spaced surrounding the plastic bubble, and a sterile enclosure which the bubble, backing strip, absorbent material and spacer are sterilely protected from external contamination-and from which the bubble and its contents may he sterilely removed.
No r e en es i e
US28109A 1960-05-10 1960-05-10 Single use, prepackaged vaccinator Expired - Lifetime US2974787A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US28109A US2974787A (en) 1960-05-10 1960-05-10 Single use, prepackaged vaccinator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28109A US2974787A (en) 1960-05-10 1960-05-10 Single use, prepackaged vaccinator

Publications (1)

Publication Number Publication Date
US2974787A true US2974787A (en) 1961-03-14

Family

ID=21841628

Family Applications (1)

Application Number Title Priority Date Filing Date
US28109A Expired - Lifetime US2974787A (en) 1960-05-10 1960-05-10 Single use, prepackaged vaccinator

Country Status (1)

Country Link
US (1) US2974787A (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136314A (en) * 1960-08-01 1964-06-09 Kravitz Harvey Vaccinating devices
US3167073A (en) * 1962-01-16 1965-01-26 Rosenthal Sol Roy Transcutaneous injection device
US3187983A (en) * 1963-04-12 1965-06-08 Jose N Mendoza Cellophane wrapper tearer
US3221739A (en) * 1962-03-26 1965-12-07 Rosenthal Sol Roy Injection device
US3291129A (en) * 1962-08-10 1966-12-13 Burelle Pierre Laurent Raymond Scarificator for use in vaccination, skin tests, or the like
EP0261149A1 (en) * 1986-03-06 1988-03-30 WRAY, Reginald Charles Skin test kit
EP0363393A1 (en) * 1987-05-29 1990-04-18 Royal North Shore Hospital Medical testing device.
US5054499A (en) * 1989-03-27 1991-10-08 Swierczek Remi D Disposable skin perforator and blood testing device
US5104620A (en) * 1990-07-30 1992-04-14 Wiley Fred R Disposable allergy skin testing kit
US5115913A (en) * 1989-06-30 1992-05-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Packaged supported pressure-sensitive adhesive plasters
US5505306A (en) * 1993-07-19 1996-04-09 Nitto Denko Corporation Package structure of drug-containing pressure-sensitive adhesive sheet
US6443307B1 (en) 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
WO2004062512A1 (en) * 2003-01-09 2004-07-29 Accelerator I Linköping Ab Skin penetration device to simultaneously introduce a plurality of substances
US20050171567A1 (en) * 2004-01-29 2005-08-04 Dehart Damon H. Lancet and method of manufacturing the same
US20050238708A1 (en) * 2004-04-23 2005-10-27 Andrew Jones Sealed capsule including an integrated puncturing mechanism
WO2007007128A1 (en) * 2005-07-08 2007-01-18 Cambridge Biostability Limited Apparatus for administrating substances into a body
US20070118070A1 (en) * 1996-06-18 2007-05-24 Cormier Michel J Device with anchoring elements for transdermal delivery or sampling of agents
US20100180894A1 (en) * 2009-01-15 2010-07-22 Andrew Jones Delivery device and related methods
US8607787B2 (en) 2007-07-06 2013-12-17 Manta Devices, Llc Dose delivery device for inhalation
WO2014036539A1 (en) * 2012-09-02 2014-03-06 Mystic Pharmaceuticals Inc. Fully self-contained unit dose devices for allergy skin testing
US8763605B2 (en) 2005-07-20 2014-07-01 Manta Devices, Llc Inhalation device
US9283336B2 (en) 2010-03-19 2016-03-15 Manta Devices, Llc Delivery device and related methods
US9649454B2 (en) 2012-05-03 2017-05-16 Manta Devices, Llc Delivery device and related methods
US20170304604A1 (en) * 2015-01-16 2017-10-26 Toppan Printing Co., Ltd. Transdermal administration device packaged body
US11103659B2 (en) 2011-07-06 2021-08-31 Manta Devices, Llc Delivery device and related methods
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136314A (en) * 1960-08-01 1964-06-09 Kravitz Harvey Vaccinating devices
US3167073A (en) * 1962-01-16 1965-01-26 Rosenthal Sol Roy Transcutaneous injection device
US3221739A (en) * 1962-03-26 1965-12-07 Rosenthal Sol Roy Injection device
US3291129A (en) * 1962-08-10 1966-12-13 Burelle Pierre Laurent Raymond Scarificator for use in vaccination, skin tests, or the like
US3187983A (en) * 1963-04-12 1965-06-08 Jose N Mendoza Cellophane wrapper tearer
EP0261149A4 (en) * 1986-03-06 1988-12-08 Wray Reginald Charles Skin test kit.
EP0261149A1 (en) * 1986-03-06 1988-03-30 WRAY, Reginald Charles Skin test kit
EP0363393A1 (en) * 1987-05-29 1990-04-18 Royal North Shore Hospital Medical testing device.
EP0363393A4 (en) * 1987-05-29 1990-06-27 Royal North Shore Hospital Medical testing device.
JPH04501212A (en) * 1987-05-29 1992-03-05 ニュー・サウス・ウェールズ州 medical test equipment
US5099857A (en) * 1987-05-29 1992-03-31 Northern Sydney Area Health Service Medical testing device with calibrated indicia
US5054499A (en) * 1989-03-27 1991-10-08 Swierczek Remi D Disposable skin perforator and blood testing device
US5115913A (en) * 1989-06-30 1992-05-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Packaged supported pressure-sensitive adhesive plasters
US5104620A (en) * 1990-07-30 1992-04-14 Wiley Fred R Disposable allergy skin testing kit
US5505306A (en) * 1993-07-19 1996-04-09 Nitto Denko Corporation Package structure of drug-containing pressure-sensitive adhesive sheet
US20070118070A1 (en) * 1996-06-18 2007-05-24 Cormier Michel J Device with anchoring elements for transdermal delivery or sampling of agents
US6443307B1 (en) 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
WO2004062512A1 (en) * 2003-01-09 2004-07-29 Accelerator I Linköping Ab Skin penetration device to simultaneously introduce a plurality of substances
US20050171567A1 (en) * 2004-01-29 2005-08-04 Dehart Damon H. Lancet and method of manufacturing the same
US8627818B2 (en) 2004-04-23 2014-01-14 Manta Devices, Llc Sealed capsule including an integrated puncturing mechanism
US8342176B2 (en) 2004-04-23 2013-01-01 Manta Devices, Llc Sealed capsule including an integrated puncturing mechanism
US7861712B2 (en) 2004-04-23 2011-01-04 Manta Product Development Sealed capsule including an integrated puncturing mechanism
US20050238708A1 (en) * 2004-04-23 2005-10-27 Andrew Jones Sealed capsule including an integrated puncturing mechanism
US20110083668A1 (en) * 2004-04-23 2011-04-14 Manta Devices, Llc Sealed capsule including an integrated puncturing mechanism
WO2007007128A1 (en) * 2005-07-08 2007-01-18 Cambridge Biostability Limited Apparatus for administrating substances into a body
US8763605B2 (en) 2005-07-20 2014-07-01 Manta Devices, Llc Inhalation device
US10632268B2 (en) 2005-07-20 2020-04-28 Manta Devices, Llc Inhalation device
US11491287B2 (en) 2005-07-20 2022-11-08 Manta Devices, Llc Inhalation device
US11672927B2 (en) 2005-07-20 2023-06-13 Manta Devices, Llc Inhalation device
US8607787B2 (en) 2007-07-06 2013-12-17 Manta Devices, Llc Dose delivery device for inhalation
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation
US9713684B2 (en) 2007-07-06 2017-07-25 Manta Devices, Llc Dose delivery device for inhalation with plunger
US9919115B2 (en) 2007-07-06 2018-03-20 Manta Devices, Llc Dose delivery device for inhalation with first and second portions to open a dose chamber
US20100180894A1 (en) * 2009-01-15 2010-07-22 Andrew Jones Delivery device and related methods
US9004064B2 (en) 2009-01-15 2015-04-14 Manta Devices, Llc Delivery device and related methods
US8550074B2 (en) 2009-01-15 2013-10-08 Manta Devices, Llc Delivery device and related methods
US9283336B2 (en) 2010-03-19 2016-03-15 Manta Devices, Llc Delivery device and related methods
US11103659B2 (en) 2011-07-06 2021-08-31 Manta Devices, Llc Delivery device and related methods
US9649454B2 (en) 2012-05-03 2017-05-16 Manta Devices, Llc Delivery device and related methods
WO2014036539A1 (en) * 2012-09-02 2014-03-06 Mystic Pharmaceuticals Inc. Fully self-contained unit dose devices for allergy skin testing
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
US10561831B2 (en) * 2015-01-16 2020-02-18 Toppan Printing Co., Ltd. Transdermal administration device packaged body
US20170304604A1 (en) * 2015-01-16 2017-10-26 Toppan Printing Co., Ltd. Transdermal administration device packaged body

Similar Documents

Publication Publication Date Title
US2974787A (en) Single use, prepackaged vaccinator
US3034507A (en) Intracutaneous injection device
EP0614652B1 (en) Sticking material for hemostasis
EP0363393B1 (en) Medical testing device
US3289670A (en) Device for abrading and applying biologicals to the skin of a patient
US3246647A (en) Disposable intracutaneous injector
US2893392A (en) Article of manufacture for intracutaneous injections
US3523011A (en) Sterilization indicator material and tape containing the same
US20130018279A1 (en) "blood sample collection apparatus and kits"
US3944069A (en) Receiver for disposable surgical implements
US3941132A (en) Interconnected surgical sponges
US3490448A (en) Adhesive pressure pad
US3481462A (en) Disposable surgical holder and counter
US4053053A (en) Venipuncture aid device
EP0254428A2 (en) Ethylene oxide sterilisation test pack
Mei Dried blood spot sample collection, storage, and transportation
US20230116245A1 (en) Disposable kit
US4635633A (en) Combination sterile pad support and lancet
VOLLMER et al. A new tuberculin patch test
US3515126A (en) Test patch for diagnosing allergies
US4829995A (en) Fluid barrier for medical dressing
US20100022973A1 (en) Method of collecting biological excretory substance
US20180132773A1 (en) Portable phlebotomy kit
WO2019190583A1 (en) Disposable kit
JPS587225A (en) Tool for fixing probe to skin surface